Spero Therapeutics Inc Cash Flow Quality Index
Spero Therapeutics Inc cash flow quality index. Spero Therapeutics Inc (SPRO) has a Cash Flow Quality Index of -0.26x as of December 2025. Operating cash flow of $-8.35 Million is below net income of $31.52 Million, suggesting accrual-heavy earnings not yet converted to cash. See financial agility of Spero Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Spero Therapeutics Inc (2023–2025)
Cash flow quality index of Spero Therapeutics Inc from 2023 to 2025. Historical Cash Flow Quality Index for Spero Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore how well can Spero Therapeutics Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Spero Therapeutics Inc Cash Flow Quality Index by Year (2023–2025)
Spero Therapeutics Inc cash flow quality index by year from 2023 to 2025. Year-by-year earnings quality comparison for Spero Therapeutics Inc. For the full cash flow conversion analysis, see how efficiently does Spero Therapeutics Inc generate cash.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -1.47x | $-12.62 Million | $8.57 Million | ▼ -1.8% |
| 2023 | -1.45x | $-32.99 Million | $22.81 Million | — |